Publications

Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.

Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al..  2023.  Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.. Blood.

Li M, Teater MR, Hong JYoung, Park NR, Duy C, Shen H, Wang L, Chen Z, Cerchietti L, Davidson SM et al..  2022.  Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival.. Blood Cancer Discov. 3(1):50-65.

Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MTeresa, Antysheva Z, Svekolkin V, Tikhonova E, Miheecheva N, Kuzkina N et al..  2021.  Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures.. Cancer Discov.

Fernando TM, Marullo R, Gresely BPera, Phillip JM, Yang SNing, Lundell-Smith G, Torregroza I, Ahn H, Evans T, Gyorffy B et al..  2019.  BCL6 evolved to enable stress tolerance in vertebrates and is broadly required by cancer cells to adapt to stress.. Cancer Discov.

Li M, Chiang Y-L, Lyssiotis CA, Teater MR, Hong JYoung, Shen H, Wang L, Hu J, Jing H, Chen Z et al..  2019.  Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.. Cancer Cell. 35(6):916-931.e9.

Du W, Goldstein R, Jiang Y, Aly O, Cerchietti L, Melnick AM, Elemento O.  2017.  Effective combination therapies for B cell lymphoma predicted by a virtual disease model.. Cancer Res.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R et al..  2015.  Epigenomic evolution in diffuse large B-cell lymphomas.. Nat Commun. 6:6921.

Tian YF, Ahn H, Schneider RS, Yang SNing, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A.  2015.  Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.. Biomaterials. 73:110-9.

Ha K, Fiskus W, Choi DSoon, Bhaskara S, Cerchietti L, Devaraj SGT, Shah B, Sharma S, Chang JC, Melnick AM et al..  2014.  Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.. Oncotarget. 5(14):5637-50.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai L-J, Leblanc M, Diehl C, Cerchietti L et al..  2012.  The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.. Cell Metab. 15(4):554-62.

Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim Y-mi, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC et al..  2011.  BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.. J Exp Med. 208(11):2163-74.

Duy C, J Yu J, Nahar R, Swaminathan S, Kweon S-mi, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L et al..  2010.  BCL6 is critical for the development of a diverse primary B cell repertoire.. J Exp Med. 207(6):1209-21.